← ANALYST RATINGS · TIPRANKS
Immunic (IMUX): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy0 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $37.38, the highest $70.00, the lowest $22.00. The average is +436.2% from the last price of $6.97.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $7.00+7.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.00 → $6.50+8.3% | Sell | −6.7% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $7.00+7.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $7.00+7.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.50 → $7.00+7.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $7.00+7.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $25.00 | Buy | +258.7% | Reiterated | 08.10.26on TipRanks 09:05 | −0.5%next day +7.7% · 5 days −5.8% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $56.00 | Buy | +703.4% | Reiterated | 11.09.26on TipRanks 09:25 | −4.4%next day −1.2% · 5 days −6.9% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $45.00 | Buy | +545.6% | Reiterated | 10.09.26on TipRanks Oct 1 10:25 | −2.3%next day −4.4% · 5 days −13.2% | ↗ |
| Unknown Analyst | Leerink Partners | — | Buy | — | Reiterated | 10.09.26on TipRanks 13:05 | −2.3%next day −4.4% · 5 days −13.2% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $22.00 | Buy | +215.6% | Reiterated | 10.09.26on TipRanks 06:45 | −2.3%next day −4.4% · 5 days −13.2% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 10.09.26on TipRanks 05:37 | −2.3%next day −4.4% · 5 days −13.2% | ↗ |
| William Wood★★★★★★★★★★#3198 · hits 53% · avg +11.7% | B. Riley Securities | $27.00 | Buy | +287.4% | Reiterated | 02.09.26on TipRanks 09:10 | −2.8%next day −11.4% · 5 days −15.9% | ↗ |
| Boobalan Pachaiyappan★★★★★★★★★★#11894 · hits 38% · avg −7.5% | Roth MKM | $19.00 → $29.00+52.6% | Buy | +316.1% | Reiterated | 01.09.26on TipRanks 06:50 | −7.0%next day −2.8% · 5 days −16.5% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $25.00 | Buy | +258.7% | Reiterated | 11.08.26on TipRanks Aug 12 10:15 | +10.1%next day +2.7% · 5 days +9.6% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $70.00 | Buy | +904.3% | Reiterated | 11.08.26on TipRanks Aug 12 07:10 | +10.1%next day +2.7% · 5 days +9.6% | ↗ |
| Jason Kolbert★★★★★★★★★★#12335 · hits 32% · avg −9.0% | D. Boral Capital | — | Hold | — | Downgrade | 15.04.26on TipRanks Apr 17 05:21 | −6.7%next day −10.2% · 5 days −20.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Immunic
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 08.10.26: target $37.38 at a price of $7.63 (+389.8%); now: $37.38 at $6.97 (+436.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 13 | 11 | 5 | 10 | 11 |
| Buy | 3 | 2 | 1 | 2 | 4 | 4 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.94 (from $-2.58 to $-0.60). Last quarter: $-0.80.
Best top-analyst consensus in the sector · Healthcare
About Immunic
- CEO: Erik Lundgren
- Employees: 100
- 1200 Avenue of the Americas, New York City, NY, 10036, US
- imux.com
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗